Literature DB >> 1355078

Upregulation of adhesion molecules induced by broncho-vaxom on phagocytic cells.

J Duchow1, A Marchant, J P Delville, L Schandene, M Goldman.   

Abstract

Whole blood was incubated with the bacterial extract Broncho-Vaxom (OM85) at various concentrations and for different periods of time. Expression of the beta 2-integrins (LFA-1, CD11a/CD18; MAC-1, CD11b/CD18; p150,95, CD11c/CD18) and ICAM-1 (CD54) by monocytes and granulocytes was studied using flow cytometry. OM85 enhanced the expression of MAC-1 and ICAM-1 on monocytes and granulocytes in a dose-dependent manner. Maximal expression was achieved with 1 mg/ml bacterial extract. The effect on MAC-1 expression was not due to the low concentration of endotoxin contaminating the preparation (less than 1 ng/mg) since polymyxin-B did not substantially affect the adhesion molecule upregulation induced by OM85. In addition, OM85 enhanced the expression of p150,95 on monocytes and granulocytes, and also increased expression of LFA-1 on monocytes, but not on granulocytes. While MAC-1 and p150,95 expression reached peak values between 1 and 6 h, levels of ICAM-1 rose constantly for 10 h. We suggest that the clinical interest of OM85 in the management of recurrent infections could be related to be upregulation of adhesion molecules induced by this bacterial extract.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1355078     DOI: 10.1016/0192-0561(92)90073-t

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  8 in total

1.  Differential up-regulation of circulating soluble and endothelial cell intercellular adhesion molecule-1 in mice.

Authors:  S Komatsu; S Flores; M E Gerritsen; D C Anderson; D N Granger
Journal:  Am J Pathol       Date:  1997-07       Impact factor: 4.307

2.  Induction of interleukin 6 and interleukin 8 expression by Broncho-Vaxom (OM-85 BV) via C-Fos/serum responsive element.

Authors:  R Keul; M Roth; E Papakonstantinou; M Nauck; A P Perruchoud; L H Block
Journal:  Thorax       Date:  1996-02       Impact factor: 9.139

3.  Broncho-Vaxom® (OM-85 BV) soluble components stimulate sinonasal innate immunity.

Authors:  Vasiliki Triantafillou; Alan D Workman; Neil N Patel; Ivy W Maina; Charles C L Tong; Edward C Kuan; David W Kennedy; James N Palmer; Nithin D Adappa; Salomon Waizel-Haiat; Noam A Cohen
Journal:  Int Forum Allergy Rhinol       Date:  2019-01-07       Impact factor: 3.858

4.  Prevention of recurrent rhinopharyngitis in at-risk children in France: a cost-effectiveness model for a nonspecific immunostimulating bacterial extract (OM-85 BV).

Authors:  Jean-Jacques Pessey; Françoise Mégas; Benoît Arnould; Florence Baron-Papillon
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

5.  Prospective, randomized comparison of OM-85 BV and a prophylactic antibiotic in children with recurrent infections and immunoglobulin A and/or G subclass deficiency.

Authors:  Ferah Genel; Necil Kutukculer
Journal:  Curr Ther Res Clin Exp       Date:  2003-09

6.  Broncho Vaxom (OM-85) modulates rhinovirus docking proteins on human airway epithelial cells via Erk1/2 mitogen activated protein kinase and cAMP.

Authors:  Michael Roth; Christian Pasquali; Daiana Stolz; Michael Tamm
Journal:  PLoS One       Date:  2017-11-28       Impact factor: 3.240

7.  Prevention of respiratory tract infections with bacterial lysate OM-85 bronchomunal in children and adults: a state of the art.

Authors:  Fernando De Benedetto; Gianfranco Sevieri
Journal:  Multidiscip Respir Med       Date:  2013-05-22

8.  IRF7-Associated Immunophenotypes Have Dichotomous Responses to Virus/Allergen Coexposure and OM-85-Induced Reprogramming.

Authors:  Emma de Jong; Jean-Francois Lauzon-Joset; Jonatan Leffler; Michael Serralha; Alexander N Larcombe; Claus T Christophersen; Patrick G Holt; Deborah H Strickland; Anthony Bosco
Journal:  Front Immunol       Date:  2021-07-22       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.